Colony formation assays indicated a higher number of clones in HER2-positive breast cancer cells treated with both trastuzumab and 13(S)-HODE (Supplementary figure 6C), the results were also consistent with the treatment with pyrotinib (Supplementary figure 6D) and lapatinib (Supplementary figure 6E). This evidence concerns the gene ERBB2 and breast carcinoma.